AKEBIA THERAPEUTICS, INC. (AKBA) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.03; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.03; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.00; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.00; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $0.89
- Previous close
- $0.89
- Change
- -$0.01
- Change (%)
- -0.78%
- Close date
- 2026-09-29
- Previous close date
- 2026-09-28
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- AKBA
- -44.97%
- S&P 500
- (m)
1 year
- AKBA
- -67.31%
- S&P 500
- (m)
3 years
- AKBA
- -22.28%
- S&P 500
- (m)
5 years
- AKBA
- -69.02%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.03
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.03 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -0.03 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | 0.00 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | 0.00 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | 0.03 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -0.02
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -0.02 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -0.33 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -0.28 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -0.52 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -1.70 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 49.13M ■ Earnings -8.91M — Profit margin -18.13%
31 Dec 2025 ■ Revenue 236.20M ■ Earnings -5.30M — Profit margin -2.24%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $0.89 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning AKBA
View more →(m)
Statistics
View more →Retained observations as of 2026-11-13; financial period ending 30 Jun 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-29.62M
- Profit margin
- -13.52%
- Return on assets · 12 month
- -8.52%
- Index membership
- (m)
- Employees
- 194.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 6.74M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -9.59%*
- Total return · month
- 0.80%*
- Total return · quarter
- -20.18%*
- Total return · half year
- -33.88%*
- Total return · year to date
- -44.97%*
- Total return · 1 year
- -67.31%*
- Total return · 3 years
- -22.28%*
- Total return · 5 years
- -69.02%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- $219.06M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- 198.11%*
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
AKEBIA THERAPEUTICS, INC. Overview
View more →(m)
(m)
- SEC CIK
- 1517022
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 245 FIRST STREET, CAMBRIDGE, Massachusetts, 02142, United States
- Fiscal year end
- 1231
- Phone
- 617-871-2098
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |